Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2017
At a glance
- Drugs Pegargiminase (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Polaris Pharmaceuticals
- 06 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
- 06 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2017.
- 25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 May 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History